KaydedilenlerDerginizi ekleyin

Dergiler / European Archives of Medical Research / 2021 / Cilt: 37 - Sayı: 1

Short-term Efficacy of Dienogest in Improving Pain in Patients with Endometriosis: A Single-center Experience

Murat EKİN
Cihan KAYA
Hüseyin CENGİZ
İsmail ALAY
Levent YAŞAR
Ece BAHÇESİ
Sayfa
11–14
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

A significantdifference was found in the reduction of dysmenorrhea, dyspareunia, dyschezia, and pelvic pain VAS scores between the study groups, andmore reduction was observed in the DNG group after 6 months of follow-up (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Endometriosis is a common disease that affects 5%-15% of women of reproductive age.
📊
Temel Bulgular & Veri:This study aimed to evaluate the effect ofdienogest (DNG) on improving pain scores of patients with endometriosis.Methods: Data of 77 women who were admitted to the endometriosis clinic from March 1, 2015, to March 1, 2017, were evaluated.
💡
Sonuç & Katkı:A significantdifference was found in the reduction of dysmenorrhea, dyspareunia, dyschezia, and pelvic pain VAS scores between the study groups, andmore reduction was observed in the DNG group after 6 months of follow-up (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2015 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Endometriosis is a common disease that affects 5%-15% of women of reproductive age. This study aimed to evaluate the effect ofdienogest (DNG) on improving pain scores of patients with endometriosis.Methods: Data of 77 women who were admitted to the endometriosis clinic from March 1, 2015, to March 1, 2017, were evaluated. Patientswere divided into 2 groups: DNG group (n=46) or group that denied use of any medication (expectant management group, n=31). The mainpresenting symptoms were graded using the visual analog scale (VAS). Age, parity, gravidity, body mass index (BMI), VAS scores, and furthersurgery requirement of the study groups were compared.Results: The most common presenting symptom was dysmenorrhea (79.2%), and the least common was dysuria (7.8%). No statisticallysignificant difference was found between the study groups in terms of age, parity, gravidity, BMI, and further surgery requirement. A significantdifference was found in the reduction of dysmenorrhea, dyspareunia, dyschezia, and pelvic pain VAS scores between the study groups, andmore reduction was observed in the DNG group after 6 months of follow-up (p

🔖

Bu Makaleye Atıf Yap

EKİN, M., KAYA, C., CENGİZ, H., ALAY, İ., YAŞAR, L., BAHÇESİ, E. (2022). Short-term Efficacy of Dienogest in Improving Pain in Patients with Endometriosis: A Single-center Experience. European Archives of Medical Research, Cilt: 37 - Sayı: 1, 11–14. https://ajindex.com/articles/510301

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Podgaec S, Rizzo LV, Fernandes LF, Baracat EC, Abrao MS. CD4(+) CD25(high) Foxp3(+) cells increased in the peritoneal fluid of patients with endometriosis. Am J Reprod Immunol 2012;68:301-8
  2. Giudice LC, Kao LC. Endometriosis. Lancet 2004;364:1789-99
  3. Vercellini P, Crosignani P, Somigliana E, Viganò P, Frattaruolo MP, Fedele L. ‘Waiting for Godot’: a commonsense approach to the medical treatment of endometriosis. Hum Reprod 2011;26:3-13
  4. Vercellini P, Eskenazi B, Consonni D, Somigliana E, Parazzini F, Abbiati A, et al. Oral contraceptives and risk of endometriosis: a systematic review and meta-analysis. Hum Reprod Update 2011;17:159-70
  5. Olive DL, Pritts EA. Treatment of endometriosis. N Engl J Med 2001;345:266-75
  6. Crosignani P, Olive D, Bergqvist A, Luciano A. Advances in the management of endometriosis: an update for clinicians. Hum Reprod Update 2006;12:179-89
  7. Sitruk-Ware R, Nath A. The use of newer progestins for contraception. Contraception 2010;82:410-7
  8. Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis. Int J Gynaecol Obstet 2010;108:21-5
  9. Andres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet 2015;292:523-9
  10. Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis–a randomized, doubleblind, multicenter, controlled trial. Fertil Steril 2009;91:675-81
  11. Fuentes-Márquez P, Cabrera-Martos I, Valenza MC. Physiotherapy interventions for patients with chronic pelvic pain: A systematic review of the literature. Physiother Theory Pract 2019;35:1131-8
  12. Johnson NP, Hummelshoj L; World Endometriosis Society Montpellier Consortium. Consensus on current management of endometriosis. Hum Reprod 2013;28:1552-68
  13. Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2012;2012:CD002122
  14. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, doubleblind, placebo-controlled study. Eur J Obstet Gynecol Reprod Biol 2010;151:193-8
  15. Cosson M, Querleu D, Donnez J, Madelenat P, Konincks P, Audebert A, et al. Dienogest is as effective as triptorelin